Free Trial
NASDAQ:TRVN

Trevena Earnings Date & Estimates

Trevena logo
$0.0005 0.00 (0.00%)
As of 11/13/2026 03:42 PM Eastern

Trevena is estimated to report earnings on Monday, November 16, 2026.

What Analysts Expect from Trevena

Trevena is expected to post earnings of -$50.00 per share on revenue of $782 thousand. Trevena has beaten the consensus EPS estimate in 5 of its last 7 quarters.

Consensus Estimates

Consensus EPS
-$50.00
Expected Revenue
$782 thousand

Recent Track Record

Last Reported
Q3 2024
Last Quarter EPS
-$5.79
Last Quarter Revenue
$280 thousand
EPS Beat Rate
5 of last 7 quarters

Trevena Earnings FAQ

Trevena (NASDAQ:TRVN) is estimated to report earnings on Monday, November 16, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Trevena to post earnings of -$50.00 per share for the quarter.

The consensus revenue estimate for Trevena is $782 thousand for the quarter.

Trevena Earnings Headlines

Trevena Inc.
Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
Trevena, Inc. (TRVN) - Yahoo Finance
See More Trevena Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Trevena? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Trevena and other key companies, straight to your email.

About Trevena

Trevena (NASDAQ:TRVN) is a biopharmaceutical company focused on developing medicines for the treatment of acute and chronic pain, as well as disorders of the central nervous system. The company’s research has centered on G protein–coupled receptors and its “biased ligand” drug-discovery platform, which is intended to produce therapeutic effects while potentially reducing certain side effects associated with conventional treatments.

Trevena’s principal commercial product is OLINVYK (oliceridine) injection, an opioid analgesic approved by the U.S. Food and Drug Administration in 2020 for the management of acute pain severe enough to require an intravenous opioid analgesic in adults. The product was developed for use in hospital and other medically supervised settings. Trevena has also investigated additional candidates, including oral and injectable therapies designed to address pain and central nervous system conditions.

Founded in 2007 and headquartered in Chesterbrook, Pennsylvania, Trevena has historically operated primarily as a U.S.-based biotechnology company, with its lead product regulated and marketed in the United States. The company has undergone strategic and operational changes as it evaluated commercialization and development priorities. Its leadership has included biotechnology executive Carrie B. Jones, M.D., M.B.A., who served as president and chief executive officer during a period of the company’s commercial development.

View Trevena Profile